2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1285

Markers of Non-Compliance with ASAS/EULAR Management Recommendations Among Early Spa Patients: Evidence over 3 Years in the DESIR Cohort
Abstract Number: 1286

Persistent Individual and Neighborhood Poverty Are Independent Risk Factors for Accumulated Lupus Damage
Abstract Number: 1287

Impact of Participation in Adalimumab Patient Support Program (PSP) on Clinical Outcomes and Predictors of PSP Utilization Among Patients with Rheumatoid Arthritis
Abstract Number: 1288

Dual Care Utilization in Patients Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Abstract Number: 1289

Healthcare Utilization Differences According to Sex Among Children and Adults in Medicaid with Incident Lupus Nephritis
Abstract Number: 1290

Burden of Rheumatoid Arthritis in the US Elderly Population: Comorbidities, Healthcare Resource Utilization, and Cost
Abstract Number: 1291

The Pediatric Rheumatology Workforce in 2015: A Survey of Pediatric Rheumatologists
Abstract Number: 1292

What Is the Effect of TNF Inhibitors on Employment Status in Rheumatoid Arthritis Patients and What Are the Predictors of Progression to Unemployment?
Abstract Number: 1293

A Comparison of Prenatal Care in Mothers with and without JIA: Association with Outcomes
Abstract Number: 1294

Infection and Screening Costs Related to Tumor Necrosis Factor-Alpha Inhibitor Use
Abstract Number: 1295

Online Consultation for Rheumatic Disease Patients Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Abstract Number: 1296

Evaluating Inter-Rater Reliability in Joint Count to Promote Quality and Trust in a Clinical Arthritis Care Team
Abstract Number: 1297

Improving the Medication Prior Authorization Process in a University Based Rheumatology Practice
Abstract Number: 1298

Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH): A Collaborative and Systems-Based Approach to Improve Access to Care
Abstract Number: 1299

Can Bone Marrow Lesions be Scored More Reliably and Responsively in Knee Osteoarthritis Using a Web-Based Overlay System (KIMRISS) Than By Standard MRI Osteoarthritis Knee Scoring (MOAKS)? Data from the Osteoarthritis Initiative and a Prospective Trial of Adaluminab Therapy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].